Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Payables (2016 - 2025)

Historic Payables for Spyre Therapeutics (SYRE) over the last 11 years, with Q3 2025 value amounting to $7.5 million.

  • Spyre Therapeutics' Payables rose 4437.56% to $7.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.5 million, marking a year-over-year increase of 4437.56%. This contributed to the annual value of $666000.0 for FY2024, which is 9598.41% down from last year.
  • As of Q3 2025, Spyre Therapeutics' Payables stood at $7.5 million, which was up 4437.56% from $3.7 million recorded in Q2 2025.
  • Over the past 5 years, Spyre Therapeutics' Payables peaked at $20.8 million during Q2 2023, and registered a low of $666000.0 during Q4 2024.
  • Its 5-year average for Payables is $6.2 million, with a median of $3.3 million in 2021.
  • As far as peak fluctuations go, Spyre Therapeutics' Payables skyrocketed by 234963.07% in 2023, and later tumbled by 9598.41% in 2024.
  • Spyre Therapeutics' Payables (Quarter) stood at $3.3 million in 2021, then crashed by 79.6% to $677000.0 in 2022, then soared by 2349.63% to $16.6 million in 2023, then crashed by 95.98% to $666000.0 in 2024, then surged by 1019.67% to $7.5 million in 2025.
  • Its Payables was $7.5 million in Q3 2025, compared to $3.7 million in Q2 2025 and $3.7 million in Q1 2025.